Gazelle Parent, Inc.
OBX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for OBX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OBX
Gazelle Parent, Inc. (OBX) is a pre-revenue biotechnology company focused on developing its cytoDRiVE platform and lead product candidate amsoki-cel for oncology, with no approved products and a history of operating losses.
Key risk: Dependence on amsoki-cel success
Market Cap
$1.01B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Gazelle Parent, Inc. (OBX) is a pre-revenue biotechnology company focused on developing its cytoDRiVE platform and lead product candidate amsoki-cel for oncology, with no approved products and a history of operating losses.
- As of June 30, 2026, the company had cash equivalents and short-term investments of $34.4 million, with an accumulated deficit of $341.4 million [sec · filed 2026-08-28].
- The company's lead product candidate is amsoki-cel, currently in clinical development for a registration-enabling melanoma cohort of the Agni-01 study [sec · filed 2026-08-28].
- The cytoDRiVE platform is designed to control protein activity across multiple classes of proteins and cell types, with potential applications in oncology and other therapeutic areas [sec · filed 2026-08-28].
- The company expects to continue incurring significant losses and requires additional funding to finance operations, with current capital expected to fund operations into the second half of 2028 [sec · filed 2026-08-28].
- The company has not completed development of any product candidates and faces substantial risks related to clinical development, regulatory approval, and commercialization [sec · filed 2026-08-28].
What works
- The cytoDRiVE platform is described as highly versatile and fit-for-purpose, with the ability to drive on-or-off activity across multiple classes of proteins and cell types, which may enable strategic collaborations [sec · filed 2026-08-28].
- The company believes it has sufficient capital to fund operations into the second half of 2028 based on current operating plans and recent financing [sec · filed 2026-08-28].
What to weigh
- The company has an accumulated deficit of $341.4 million as of June 30, 2026, and expects losses to increase as it advances its product candidate through clinical development [sec · filed 2026-08-28].
- The business is highly dependent on the success of amsoki-cel, and any delays or failures in clinical development, regulatory approval, or commercialization would materially harm the company [sec · filed 2026-08-28].
- The company will require additional funding to finance operations, and if unable to raise capital on acceptable terms, it may be forced to delay or reduce development programs [sec · filed 2026-08-28].
From the filings
Quoted directly from source documents.
The company's lead product candidate is amsoki-cel, and its clinical trial is the Agni-01 study with a registration-enabling melanoma cohort.
“If we experience delays in enrollment or completion of, or the suspension or termination of, any clinical trial of our lead product candidate, amsoki-cel, including the registration-enabling melanoma cohort of our Agni-01 study”
SEC filings · August 28, 2026
The company has an accumulated deficit of $341.4 million as of June 30, 2026.
“As of June 30, 2026, we had an accumulated deficit of $341.4 million.”
SEC filings · August 28, 2026
The company expects to fund operations into the second half of 2028.
“we believe we have sufficient capital to fund our operations into the second half of 2028.”
SEC filings · August 28, 2026
Risks & what to watch (4)›
Key risks
- Dependence on amsoki-cel success — The company's future is highly dependent on the successful development and commercialization of amsoki-cel; any failure would materially harm the business [sec · filed 2026-08-28].
- Need for additional funding — The company requires additional capital to finance operations; inability to raise funds may force reduction or elimination of development programs [sec · filed 2026-08-28].
- Significant accumulated deficit — As of June 30, 2026, the company had an accumulated deficit of $341.4 million and expects losses to increase [sec · filed 2026-08-28].
- Clinical and regulatory uncertainty — Delays in clinical trials, regulatory approval, or manufacturing could prevent commercialization of product candidates [sec · filed 2026-08-28].
What to watch
- Progress of the registration-enabling melanoma cohort of the Agni-01 study for amsoki-cel [sec · filed 2026-08-28].
- Ability to secure additional funding to support ongoing operations and development [sec · filed 2026-08-28].
- Potential strategic partnerships or collaborations involving the cytoDRiVE platform [sec · filed 2026-08-28].
- Cash runway and burn rate relative to the projected funding into the second half of 2028 [sec · filed 2026-08-28].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Gazelle Parent, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Gazelle Parent, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Frequently asked questions
What is the AI investment thesis for Gazelle Parent, Inc.?
Gazelle Parent, Inc. (OBX) is a pre-revenue biotechnology company focused on developing its cytoDRiVE platform and lead product candidate amsoki-cel for oncology, with no approved products and a history of operating losses.
Who is the CEO of Gazelle Parent, Inc.?
Dr. Madan Jagasia M.D., M.S. is the chief executive officer of Gazelle Parent, Inc. (OBX).
Where is Gazelle Parent, Inc. headquartered?
Gazelle Parent, Inc. (OBX) is headquartered in Cambridge, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.